The U.K. government recently released its first ever medical technology strategy which aims to accelerate access to innovative medical technologies in the NHS. Although it was welcomed by the industry, and questions remain as to whether it goes far enough to address some of the challenges to the adoption of medical devices, eyes are on its implementation and whether it will achieve its aims.
Cydar Medical Ltd. raised $11.5 million (£9.3 million) in a series A funding round which will allow it to advance its artificial intelligence (AI) surgical maps platform and bolster its ongoing commercial expansion.
Dianosic SAS recently raised €4.7 million (US$5.04 million) from investors, in its second round of financing, and will use the funds to finance its preclinical in vivo testing and launch the first phase clinical trial for its Active Resorbable Intranasal Scaffold (ARIS) solution to treat chronic allergic rhinitis.
Truleaf Medical Ltd., a subsidiary of Israel-based Allmed Solutions, is ready to begin human trials of its Rosedoc platform to replace the heart’s leaky mitral valve using cardiac catheterization.
